Fulcrum Therapeutics validates InvestingPro’s undervalued assessment with 72% rise

Fulcrum Therapeutics has confirmed InvestingPro's assessment of its undervalued status by experiencing a remarkable 72% rise in its stock price. This significant increase not only highlights the company's potential but also reinforces the credibility of InvestingPro's analysis, making it a noteworthy event for investors and market analysts alike.